/ month A 3% topical dropper solution used for scalp health, follicle regeneration, and inflammation support
Tirzepatide may be better if you: Need a medication available right now : Tirzepatide is FDA-approved and available today through clinics and pharmacies Are sensitive to GI side effects : Lower overall side effect rates at every dose level Want established safety data : Years of post-marketing surveillance data available Have insurance coverage : Mounjaro/Zepbound may be partially covered Prefer a simpler titration : Uniform 2.5 mg steps are predictable and easy to follow Are a first-time incretin user : Extensive prescriber experience means better clinical support Retatrutide may be better if you: Have significant fatty liver disease : Liver fat reduction of up to 86% is unmatched Need maximum weight loss : 28.7% at 68 weeks exceeds all other compounds Have plateaued on tirzepatide : The glucagon component offers a new mechanism Are focused on metabolic health beyond weight : Triple agonism impacts more metabolic pathways Can tolerate higher GI burden : More side effects but more results Can wait for FDA approval : Expected late 2026-2027 for regulated access Neither compound is appropriate if you: Have a personal or family history of medullary thyroid carcinoma Have multiple endocrine neoplasia syndrome type 2 Are pregnant or planning pregnancy Have a history of severe psychiatric reactions to incretin therapies Have pancreatitis history (use with extreme caution) For researchers still undecided, the semaglutide vs tirzepatide comparison page provides additional context on how dual agonists compare to single agonists
For the complete 90837 rate breakdown by provider type including commercial payer benchmarks, see our CPT 90837 reimbursement rates by provider type guide
The most common side effects of this medicine include abdominal pain, indigestion, los of appetite, nausea, vomiting, tiredness, hair loss, and low blood platelets
Customer care no: 0861 999 004
Repeated injectable copper peptide administration could theoretically alter copper balance a particular concern for individuals with Wilsons disease (copper accumulation disorder) or Menkes disease (copper deficiency disorder)
